Compare Citius Pharmaceuticals Inc (CTXR) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Logitech International SA — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Logitech International SA trades at $101.34 (market cap $14.63B). The key difference: Logitech International SA is far larger — about 1060.9× Citius Pharmaceuticals Inc's market cap, and Logitech International SA pays a 1.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Logitech International SA for 92 Days on average.
| CTXR | LOGI | |
|---|---|---|
Market Cap | $13.79M | $14.63B |
Volume | 156,684 | 440,764 |
Sector | Health | Technology |
52-Week High | $1.82 | $126.69 |
52-Week Low | $0.48 | $85.84 |
Typical Hold Time | 16 Days | 92 Days |
Enterprise Value | $3.96M | $12.96B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
Logitech (LOGI) trades at $101.50, down 0.89% today, with a bullish technical signal and strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $1.85 versus $1.26 expected, highlight operational strength. The company maintains robust profitability with a net margin of 16.28% and ROE of 35.29%, supported by new product launches like the Zone Vibe Pro headset and gaming partnerships.
Outlook remains positive with analyst consensus target of $107, offering ~5% upside, though risks include chip shortages and competitive pressures. Revenue growth is projected to reach $4.9B in 2026, but investor sentiment is mixed amid macroeconomic headwinds. The stock's valuation at P/E 18.75 appears reasonable given earnings trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
